CCNE1

CCNE1

A gene on chromosome 19q12 that encodes cyclin E1, which forms a complex with and acts as a regulatory subunit of CDK2. Cyclin E1 is required for cell cycle G1/S (start) transition; it accumulates at the G1-S phase boundary and is degraded as cells progress through S phase. It is highly expressed in the testes and placenta.
Mentioned in ?
References in periodicals archive ?
Approximately 20% of high grade serous ovarian cancers harbor CCNE1 amplification.
Candidate target genes of hsa-miR-424-5p and hsa-miR-377 Gene name Main pathway Target Accession gene ID hsa-miR-424-5p Hypoxia and angiogenesis HIF1A MIRT005926 CUL2 MIRT005927 Cell cycle CDK6 MIRT000938 CCND1 MIRT000941 CCNE1 MIRT000936 CCND3 MIRT000937 hsa-miR-377 MAPK pathway PPM1A MIRT000990 PI3K-akt pathway PAK1 MIRT000991 HIF1A: Hypoxia-inducible factor 1A; CUL2: Cullin 2; CDK: Cyclin-dependent kinase; CCND1: Cyclin D1; CCNE1: Cyclin E1; CCND3: Cyclin D3; MAPK: Mitogen-activated protein kinase; PPM1A: Protein phosphatase magnesium-dependent 1A; PI3K: Phosphatidyl inositol 3'-kinase; PAK1: p21-activated kinase 1.
Several cancer-related genes, such as TERT, MLL4, and CCNE1, can also be integrated by HBV [65].
The most-common, potentially targetable alterations were mutations, amplifications, and homozygous deletions of PIK3CA (n = 8; 40%), PTEN (n = 5; 25%), CDKN2A/B (n = 4; 20%), CCND3 (n = 3; 15%), CCNE1 (n = 2; 10%), and EGFR (n = 2; 10%), with AKT3, CCND1, CCND2, CDK4, FBXW7, FGFR1, HRAS, NF1, PIK3R1, and SRC altered in a single case (Figure 1; Table 1).
Cell-cycle alterations were common, including homozygous deletion of CDKN2A in 4 (20%) and amplifications of CCND3, CCNE1, CCND1, CCND2, and CDK4 in 8 (40%) of the MPBC cases, a subset of which may indicate the potential for use of cell-cycle inhibitors.
NGS identified genomic aberrations in AKT2, TP53, CCNE1, MYC, MCL1, and AXL.
Analyses also brought new insight regarding the survival impact of tumors containing BRCA1 or BRCA2 and CCNE1 mutations.
Statistical methods have been used to define a number of genomic regions of significant copy number alteration in serous-like tumors, including regions of focal amplification involving the MYC (v-myc avian myelocytomatosis viral oncogene homolog) oncogene, the ERBB2 (HER2) receptor tyrosine kinase gene, and CCNE1 (cyclin E1), which are each focally amplified in 23%-25% of cases (15).
Many genes whose expression is regulated by E2F family transcription factors, including CDK2, CCNE1, CDC6, CDC2, MCM2, were significantly down-regulated at 24 hr post-IR.
CCNE1 and v-myb myeloblastosis viral oncogene homolog avian-like 2 (MFBL2) are important genes involved in the [G.